



21925 Field Parkway, Suite 235
Deer Park, IL 60010 USA
Tel: 847.787.7361
etonpharma.com

Eton Pharmaceuticals, Inc. Exclusive Distribution Network for ALKINDI® SPRINKLE (hydrocortisone) oral granules

January 12, 2021

This notice provides information to eligible 340B covered entities about how to acquire ALKINDI® SPRINKLE (hydrocortisone) at the calculated 340B ceiling price. ALKINDI® SPRINKLE is a corticosteroid indicated as replacement therapy in pediatric patients with adrenal insufficiency. Eton Pharmaceuticals is committed to both patient safety and compliance with 340B program regulations. This notice specifically applies to the following NDC package configurations for ALKINDI® SPRINKLE:

Product Name/Strength	NDC
ALKINDI® SPRINKLE (hydrocortisone) oral granules 0.5mg	71863-109-50
ALKINDI® SPRINKLE (hydrocortisone) oral granules 1mg	71863-110-50
ALKINDI® SPRINKLE (hydrocortisone) oral granules 2mg	71863-111-50
ALKINDI® SPRINKLE (hydrocortisone) oral granules 5mg	71863-112-50

To ensure that patients being treated with ALKINDI® SPRINKLE receive appropriate drug and clinical counseling and to support therapeutic adherence, Eton Pharmaceuticals has developed an exclusive distribution plan to achieve these goals. All customers desiring to dispense ALKINDI® SPRINKLE – 340B-eligible and otherwise – are equally subject to this distribution plan. Eton Pharmaceuticals operates an exclusive distribution network composed of one (1) specialty distributor. This network was established to ensure the appropriate, consistent and efficient delivery of ALKINDI® SPRINKLE to patients that have been prescribed ALKINDI® SPRINKLE, in addition, to supporting broad access to this medicine. Eligible 340B covered entities looking to purchase ALKINDI® SPRINKLE, please contact our specialty distribution partner, AnovoRx Group, LLC at 833-343-2500 to arrange for AnovoRx Group, LLC to service the 340B covered entity as a contract 340B pharmacy and to dispense ALKINDI® SPRINKLE directly to the covered entity’s patients. Any Covered Entity desiring to contract with AnovoRx Group, LLC as a contract pharmacy is subject to certain contractual terms and conditions established by AnovoRx Group, LLC.

Because ALKINDI® SPRINKLE is an orphan drug, it is not available at the 340B ceiling price to free-standing cancer hospitals, critical access hospitals, sole community hospitals, or rural referral centers (for purposes of this notice, “Excluded Entities”). Of course, Excluded Entities may obtain ALKINDI® SPRINKLE through the channels described above at current commercially available prices subject to the other provisions set forth herein.

Eton Pharmaceuticals is committed to compliance with its obligations under the 340B statutes and works to ensure that ALKINDI® SPRINKLE is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B entities. If you have questions about this plan or about obtaining ALKINDI® SPRINKLE at the prevailing 340B ceiling price for your eligible patients, please do not hesitate to contact Scott Grossenbach at sgrossenbach@etonpharma.com. Please feel free to share this letter and the information contained herein with other 340B covered entities.